Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1813477 | 0.92 | KDM1A (0.40) | KDM1AKDM1BKCNH2CHRNB2CHRNB4 | |
| SCHEMBL25593106 | 0.78 | KDM1A (0.33) | KDM1AKDM1BKCNH2 | |
| SCHEMBL20263723 | 0.77 | NPC1 (0.32) | — | |
| SCHEMBL1229319 | 0.77 | CYP11B1 (0.30) | CYP11B1CYP11B2 | |
| SCHEMBL26122002 | 0.74 | HTR2C (0.37) | KDM1AALDH1A1 | |
| SCHEMBL4274254 | 0.73 | ALDH1A1 (0.43) | KDM1AKDM1BCYP11B1CYP11B2DPP4 | |
| SCHEMBL21408540 | 0.71 | KDM1A (0.43) | KDM1AKDM1BKCNH2 | |
| SCHEMBL1662324 | 0.70 | KDM1A (0.50) | KDM1AKDM1BKCNH2CYP11B1CYP11B2 | |
| SCHEMBL1765254 | 0.70 | DYRK1A (0.34) | ALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL6616813 | 0.69 | ALDH1A1 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190701-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2467385-A1 | RENIN INHIBITORS | Merck Canada Inc. (CA) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011020193-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190701-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | KDM1A 3480/4885KDM1B 3727/4885KCNH2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.